|The following article features coverage from the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference in Anaheim, California. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
Lanreotide depot is effective among patients with or without previous octreotide treatment for carcinoid syndrome (CS), according to a poster presented at the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference.1
The phase 3 ELECT trial (ClinicalTrials.gov Identifier: NCT00774930) previously demonstrated that lanreotide depot improved symptom control of CS and reduced the need for octreotide rescue medication among patients with a neuroendocrine tumor (NET). The purpose of this subanalysis was to determine if there are differences in lanreotide depot efficacy among patients with or without prior octreotide treatment.
The double-blind, open-label ELECT trial randomly assigned 115 patients with NET experiencing CS to receive 120 mg of lanreotide depot every 4 weeks or placebo.
The subanalysis included 51 patients who were octreotide-naïve and 64 patients previously treated with octreotide.
Treatment with lanreotide depot resulted in a greater complete response compared with placebo in both the octreotide-naïve group (34.6% vs 20%, respectively; odds ratio [OR], 2.33; 95% CI, 0.6-9.1; P = .2203) and prior octreotide group (57.6% vs 35.5%, respectively; OR, 2.47; 95% CI, 0.9-6.8; P = .0817).
The authors suggest that a higher complete response was observed in the previously treated group because their symptoms were controlled with octreotide prior to random assignment.
Lanreotide depot treatment also decreased the use of short-acting octreotide rescue medication compared with placebo in both the octreotide-naïve group (56.9% vs 27.8%, respectively) and the previously treated group (42.2% vs 35.3%, respectively).
The number of days with moderate to severe diarrhea or flushing were also lower among patients treated with lanreotide, regardless of prior treatment with octreotide.
These findings indicate that lanreotide depot improves CS-related symptoms among all patients, though results from the long-term extension study will provide additional safety and efficacy data.
Read more of Cancer Therapy Advisor‘s coverage of the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference by visiting the conference page.
- Anselmo L, Fisher GA, Wolin EM, et al. Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): subanalysis of patient-reported symptoms from the phase 3 ELECT study. Poster presented at: 13th Hematology/Oncology Pharmacy Association Annual Conference; March 29-April 1, 2017; Anaheim, CA.